Huiyu Pharmaceutical (688553.SH): HY05350 for injection obtained approval notice for drug clinical trials

Zhitong Finance App News, Huiyu Pharmaceutical (688553.SH) issued an announcement. Recently, Sichuan Huiyu Haiyue Pharmaceutical Technology Co., Ltd. (“Huiyu Haiyue”), a wholly-owned subsidiary of the company, received the “Drug Clinical Trial Approval Notice” approved by the State Drug Administration, and clinical trials for injectable HY05350 (project R&D code “HY-0005”) for the treatment of advanced solid tumors were approved.

Studies have shown that HY05350 can recognize and recruit T cells through CD3 antibodies, identify and target tumor cells through MSLN antibodies and/or PD-L1 antibodies, and reactivate immune cells by canceling the immunosuppressive effects of tumor cells on T cells through PD-L1 antibodies. Compared to normal tissue, MSLN is highly expressed in various solid tumors such as gastric cancer, lung cancer, and pancreatic cancer. Early preclinical studies showed that HY05350 showed good anti-tumor effects and safety, and had great clinical development value. HY05350 for injection is an innovative therapeutic biological product that has not been marketed at home or abroad, and has clinical development value.